Reduce the need for
opioids while providing
long-lasting pain control...
all from a single dose
•
Indicated for single-dose administration
into the surgical site to produce
postsurgical analgesia
•
DepoFoam
®
uniquely delivers bupivacaine
over time
1
•
Eliminates the need for catheters and
pumps that may hinder recovery
2-5
•
Demonstrated safety and tolerability
profile similar to placebo
•
Dose based on the administration site and
the volume required to cover the area
In the management of postsurgical pain
A S M O O T H S TA R T T O R E C O V E R Y B E G I N S W I T H E X PA R E L
©2015 Pacira Pharmaceuticals, Inc., Parsippany, NJ 07054
PP-EX-US-0778 05/15
The clinical benefit of the decrease in opioid consumption has not been demonstrated.
Important Safety Information
EXPAREL is contraindicated in obstetrical paracervical block anesthesia. EXPAREL has not been studied for use
in patients younger than 18 years of age. Non-bupivacaine-based local anesthetics, including lidocaine, may
cause an immediate release of bupivacaine from EXPAREL if administered together locally. The administration
of EXPAREL may follow the administration of lidocaine after a delay of 20 minutes or more. Other formulations
of bupivacaine should not be administered within 96 hours following administration of EXPAREL. Monitoring of
cardiovascular and neurological status, as well as vital signs should be performed during and after injection of
EXPAREL as with other local anesthetic products. Because amide-type local anesthetics, such as bupivacaine,
are metabolized by the liver, EXPAREL should be used cautiously in patients with hepatic disease. Patients with
severe hepatic disease, because of their inability to metabolize local anesthetics normally, are at a greater risk of
developing toxic plasma concentrations. In clinical trials, the most common adverse reactions (incidence ≥10%)
following EXPAREL administration were nausea, constipation, and vomiting. Studies demonstrating the safety
and efficacy of EXPAREL were conducted in hemorrhoidectomy and bunionectomy; EXPAREL has not been
demonstrated to be safe and effective in other procedures.
Please see brief summary of Prescribing Information on reverse side.
For more information, please visit www.EXPAREL.com or call 1-855-RX-EXPAREL (793-9727).
References: 1. How DepoFoam
®
works. Pacira Pharmaceuticals, Inc. website. http://www.exparel.com/how-to-use/about-depofoam.shtml. Accessed February 25, 2015. 2. Process for handling elastomeric
pain relief balls (ON-Q PainBuster and others) requires safety improvements. Institute for Safe Medication Practices website. https://www.ismp.org/newsletters/acutecare/articles/20090716.asp. Accessed
June 19, 2014. 3. I-Flow ON-Q pump with ONDEMAND bolus button. US Food and Drug Administration website. http://www.fda.gov/MedicalDevices/Safety/ListofRecalls/ucm317826.htm. Accessed January 5, 2015.
4. Continuous peripheral nerve blocks in outpatients. NYSORA–The New York School of Regional Anesthesia website. http://www.nysora.com/regional-anesthesia/foundations-of-ra/3055-continuous-peripheral-
nerve-blocks-in-outpatients.html. Accessed January 5, 2015. 5. Frost & Sullivan. New opportunities for hospitals to improve economic efficiency and patient outcomes: the case of EXPAREL™, a long-acting,
non-opioid local analgesic. http://www.frost.com/prod/servlet/cpo/252218999. Accessed January 5, 2015. 6. Data on file. Parsippany, NJ: Pacira Pharmaceuticals, Inc.; February 2015.
Used in more than
1 million patients since 2012
6
